Fig. 4

ERK pathway regulating IL4/IL4Rα-mediated proliferation of early OCPs. A Western blotting showed the protein level of ERK pathway, JAK-STAT pathway and PI3K-AKT pathway. (n = 3) B Flow cytometry plots and quantification of BrdU( +) early OCPs after treated by recombinant IL-4 protein with/without each antagonist of ERK pathway, JAK-STAT pathway and PI3K-AKT pathway, respectively. (n = 3) C Flow cytometry plots and quantification of the percentage of BrdU( +) early OCPs in bone marrow at 10 days post injection of MC-38 cells after treated by Ravoxertinib. (n = 6, each sample was pooled from 3 mice) D Flow cytometry plots and quantification of percentage of BrdU( +) early OCPs cultured in CT-26 CM after treated with IL-4 plus Ravoxertinib or not. (n = 5) E Flow cytometry plots and quantification of the percentage of BrdU( +) early OCPs in bone marrow at 10 days post injection of CT-26 cells after treated by Ravoxertinib. (n = 8, each sample was pooled from 3 mice) *p < 0.05, **p < 0.01, ***p < 0.001. Rav Ravoxertinib, Ocl Oclacitinib